Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
Date:11/6/2013

hase 3 clinical trial for Dupuytren's contracture, partially offset by lower spending on XIAFLEX  clinical trials for the treatment of Peyronie's disease.On a non-GAAP basis, selling, general and administrative costs for the quarter ended September 30, 2013 were $55.2 million, compared to $52.6 million in the comparable 2012 period.  This increase was primarily due to the added expenses of the acquired Actient operations and an increase in marketing and advertising spend related to the potential launch, if approved, of XIAFLEX for the treatment of Peyronie's disease, partially offset by lower advertising spending for Dupuytren's Contracture and non-cash costs included in the third quarter of 2012 for the now mutually terminated Testim co-promotion agreement with GSK.The non-GAAP net income for the third quarter of 2013 was $8.5 million, or $0.17 per share, (basic and fully diluted) compared to non-GAAP net loss of ($6.9) million, or ($0.14) per share, (basic and fully diluted) for the third quarter of 2012.

As of September 30, 2013, Auxilium had $121.4 million in cash, cash equivalents and short-term investments, compared to $157.4 million at December 31, 2012, and outstanding debt of $291.0 million ($350.0 million at par value) in Convertible Notes and $257.8 million ($268.8 million par value) in a senior secured term loan.

The foregoing non-GAAP financial measures should not be relied upon as an alternative to GAAP measures.  A description of the non-GAAP calculations and reconciliation to the closest comparable GAAP measure, as well as the Company's rationale for the utility to investors of the non-GAAP measures it has elected to report, is provided in the accompanying tables 2 and 3 captioned "Reconciliation of GAAP to Non-GAAP Net Income (Loss)."

Updated Guidance:
Management is updating previously announced guidance for 2013 as follows (in millions of dollars):
 UpdatedPriorGuidanceGuidance1XIAFLE
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
3. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
4. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
5. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
6. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
7. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
9. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
11. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... how to optimize a product,s web presence to ... critical. Brand websites, in particular, must meet the ... in regulations and culture. According ... LLC, more than half of the participating companies ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2
... Continued Safety, Consistently Positive Clinical ... Results ... today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated continued,positive, ... Stent System at one year, including continued,clinical superiority in major ...
... WASHINGTON, Oct. 22 The preliminary results ... OrbusNeich,s pro-healing stent, the,Genous Bio-engineered R stent, ... risk of restenosis patients show comparable efficacy ... de Winter, M.D., Ph.D.,principal investigator and director ...
Cached Medicine Technology:Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis 2
(Date:12/22/2014)... Petersburg, FL (PRWEB) December 22, 2014 Christmas ... Sublime Beauty® has a fast and easy solution that will ... gift cards can be purchased from from $25 up to ... "We offer 100% customer satisfaction and a wide array of ... have no fees and no expiration dates. , Gift ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... 22, 2014 Recently, BambooFlooringChina.com, a famous ... woven bamboo flooring collection , and launched a bamboo ... promotion is valid until Jan. 30, 2015. , According ... is the hardest bamboo flooring available today; it has ... of traditional teak hardwoods. Strand woven bamboo is made ...
(Date:12/21/2014)... Gables, FL (PRWEB) December 21, 2014 When ... head lice, who do they call? The new answer is ... Blvd, Coral Gables FL 33134, their newest treatment center will ... this pest quickly, conveniently and without the use of harmful ... Opening is scheduled for January 1, 2015. Like the company’s ...
(Date:12/21/2014)... 2014 Recently, one of the best ... Prom Shop has introduced its new collection of ... big discounts on all its prom dresses & other ... insists on providing top quality dress products and great ... considered as one of the best prom dresses online ...
Breaking Medicine News(10 mins):Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2
... (AMS), which affects about half of those ascending to heights ... pulmonary or cerebral edema. ,The interest of the general ... past 25 years. This change is partly due to media ... In spite of these apparent changes, it is unknown whether ...
... deadly bird flu since it is still rampant in the region, ... ,"I think countries in this part of the world have ... it, the virus is still circulating," said Shigeru Omi, WHO's regional ... We remain concerned. We must avoid human transmission," he told reporters ...
... patients who have already gone blind in one eye ... and Therapeutics Bulletin (DTB). ,But that is ... (NICE), the body responsible for guiding the NHS on ... (Lucentis) and pegaptanib (Macugen) are licensed in the UK ...
... Biotechnology Co., Ltd. announced that a team led by ... completed a study to assess clinical efficacy, safety, ... for patients with peripheral vascular disease of the lower ... research and treatments for ataxia, cerebral palsy, spinal cord ...
... Those involved in biological weapons programs should be logically liable ... it seems to have happened in US and the Centers ... research laboratory at Texas A&M University to stop all work ... investigating reports of lab workers infected with the category B ...
... personnel involved in the Iraqi invasion of 2003 have ... published ahead of print in Occupational and Environmental Medicine. ... combat to pierce armoured vehicles, and spontaneously combusts on ... breathed in or eaten/drunk in contaminated food/water. ...
Cached Medicine News:Health News:Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema 2Health News:Bird Flu in Asia Still High Risk Says WHO Official 2Health News:Draft National Policy on Sight-saving Drugs unacceptable 2Health News:Adult Stem Cells Show Promise for Peripheral Vascular Disease 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 3Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 4
... Designed for Western, Northern, or ... three gels with dimensions as large ... and internal cooling base for temperature ... attached power leads. Additional ...
... a component of Bio-Rad's modular mini electrophoresis ... high-quality blotting of mini gels. Its modular ... cm gels in just 1 hour. Cooling ... which absorbs heat generated during transfers. The ...
... Includes: 2 gel holder cassettes, ... cables, fiber pads, blot absorbent ... The Trans-Blot transfer cell, used ... supply, performs efficient, high-intensity electrophoretic ...
... Flexibility for a ... Transfers. Native Enzyme, ... Transfers. Faster, Higher-Efficiency ... High Field-Intensity Transfers ...
Medicine Products: